EBS EMERGENT BIOSOLUTIONS
Permanent stock page ↗Health Care · Russell 2000
Next earnings: not announced yet
What 6 analyst firms say about EMERGENT BIOSOLUTIONS: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
5 rated views · 6 analyst/firm records · 6 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Fewer than 4 price targets in the last 6 months (1)
- Russell 2000 · Safest consensus · 6MNot scored · Fewer than 4 price targets in the last 6 months (1)
Recent analyst activity · last 90 days
Our tracked history has 5 reports on EBS from 4 analyst firms in the last 90 days (6 firms in the past year).
Comparing each firm's latest target with its previous one: 1 left it unchanged.
No firm's latest available rating differs from its previous one.
Latest observed target change: HC Wainwright lowered its target from $12.00 (set 9 Mar 2026) to $10.00 on 10 Aug 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Benchmark | Robert Wasserman | Buy | 2 Jun 2026 | — |
| H.C. Wainwright | Raghuram Selvaraju | Buy | 9 Sep 2026 | 10.00 USD |
| JPMorgan | Jessica Fye | Sell | 21 Aug 2026 | — |
| UBS | Unnamed analyst | Buy | 2 Jun 2026 | — |
| Weiss Ratings | Unnamed analyst | — | 21 Aug 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 11 Aug 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 07:02 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.